SlideShare a Scribd company logo
E-cigarettes, which deliver nicotine without carcinogenic tar, hold the 
promise to save the lives of many smokers who switch to them, but risks 
include failure to quit cigarettes (dual use), increased initiation to nicotine 
products among youth, relapse of former smokers to e-cigarettes, and e-cigarettes 
becoming a “gateway to smoking.” To capture these uncertainties 
and weigh benefits vs. risks, prediction of e-cigarette health impacts must 
use a broad range of probability-weighted scenarios. 
© 
E-Cigarettes: Promise, Peril, and 
Probabilistic Population Prediction 
Bill Poland, PhD 
Bill.Poland@Certara.com 
INFORMS Annual Meeting, 10 November 2014
After the “cigarette century”: what’s the end game? 
© 
2 
http://www.surgeongeneral.gov/library/reports/50-years-of-progress/index.html#fullreport 
2014
Smoking still kills about 480,000 Americans per year, reducing life 
spans 11-12 years. 
© 
3 
http://www.surgeongeneral.gov/library/reports/50-years-of-progress/index.html#fullreport
Sales of e-cigarettes have been roughly doubling annually since 
US introduction in 2007 and could overtake cigarettes by 2023*, 
raising hopes and fears. 
© 
Sugerman DT. e-Cigarettes. JAMA 2014;311(2):212. http://jama.jamanetwork.com/article.aspx?articleid=1812964 
* Herzog B, Wells Fargo Securities presentation, 2014. http://www.ecigarette-politics.com/files/WF-DallasMarch2014.ppt 
4
Cigarettes deliver nicotine (addictive but relatively safe) and 
tar (toxic partially combusted tobacco); e-cigs avoid the tar. 
© 
Nicotine 
Produced by the tobacco plant as 
a natural pesticide 
• Used as a pesticide in early 1900s 
Highly addictive for many, mildly 
addictive for others 
Suggestion but no solid evidence 
linking to cancer 
• Ames assay for genotoxicity negative 
• But promotes angiogenesis and 
tumors in some experimental models 
Exposure during adolescence and 
in utero appears to cause long-term 
brain changes 
Nicotine Replacement Therapy 
(NRT) such as patches and gum, 
and drugs like Chantix, minimize 
addiction risk but have a low 
success rate 
Tar 
Contains hundreds of mutagens, 
carcinogens, and other toxins 
• “Cigarette smoking has been causally 
linked to diseases of nearly all organs 
of the body” 
• Surgeon General’s Report, 2014 
• Top diseases: lung cancer, COPD, 
CHD 
• Also diabetes, rheumatoid arthritis, and 
colorectal cancer, as well as 
inflammation and impaired immune 
function. 
Damages lungs (coats the cilia 
causing them to stop working and 
eventually die) and mouth. 
5
One eminent researcher concluded “e-cigarettes, with prudent ... 
regulations, do have the potential to make the combusting of 
tobacco obsolete ... just as digital cameras made film obsolete.” 
© 
6 Abrams DB. JAMA 2014;311(2): 135-136. http://jama.jamanetwork.com/article.aspx?articleid=1812971
Another researcher emphasizes a worst-case scenario. 
Time for probabilistic modeling! 
© 
Best Case 
Massive migration of smokers into e-cig 
vaping 
• Like digital cameras replacing film 
• CV and respiratory disease decline, 
followed by cancers 
Dual use is temporary 
Many e-cig users then quit nicotine 
entirely 
• Users work their way down to low 
and no-nicotine e-cigs 
• Total nicotine use drops 
Youths who would have smoked take 
up e-cigs instead 
Long-term vapor inhalation is found 
safe. 
Worst Case 
Massive migration of smokers and non-smokers 
into e-cig vaping 
• Like cell phone adoption 
• Non-users drawn in by purported safety 
Dual use persists 
• Mortality benefit of fewer cigarettes 
smoked/day is less than hoped 
E-cigs attract youth and experimenters, 
addict them to nicotine, and become a 
“gateway to smoking” 
E-cigarette advertising renormalizes 
tobacco product use so that smoking 
prevalence increases. 
Long-term exposure to fine particles in 
vapor turns out to be harmful. 
7
Mendez D 2011. Modeling the Population Dynamics of Smoking Prevalence and Health Effects, Washington DC, 9 May2011. 
© 
Population models predict smoking prevalence and 
mortality under various scenarios. 
8 
http://www.iom.edu/~/media/Files/Activity%20Files/PublicHealth/ReducedRiskTobacco/MendezPresentation.pdf
Mortality risk relative to nonsmokers has been modeled vs. years 
since quitting. Quitting by 40 may return risk to non-smoker levels. 
Mendez D, Warner KE 2001. “The relative risk of death for former smokers: the influence of age and years-quit.” Unpublished 
© 
9 
research monograph. www.umich.edu/~dmendez/tobacco/RRiskmonograph.doc
Few attempts have been made to relate mortality to use levels 
(intensity)—important with e-cigs. Here a Tobacco Exposure Index 
balances lifetime smoke toxin accumulation with natural purging. 
Miller LS et al. 2010. Evaluation of the economic impact of California’s Tobacco Control Program: a dynamic model 
approach. Tobacco Control 19(Suppl 1):i68-i76. http://tobaccocontrol.bmj.com/content/19/Suppl_1/i68.full.pdf 
© 
10 
2 packs/day never-smoker
A new generation of population models tries to predict 
effects of two tobacco products and dual use. 
Verzi S 2014. 
http://www.fda.gov/downloads/Advis 
oryCommittees/CommitteesMeetingMa 
terials/TobaccoProductsScientificAdvis 
oryCommittee/UCM394231.pdf 
© 
11 
Cigarette/e-cig 
“gateway 
to smoking” 
relapse 
by former 
smoker 
via e-cigs
© 
Even with simplifications, over a dozen highly uncertain 
transition rates remain. 
12 
Cigarette/e-cig 
x 
x x 
x 
x 
x 
Assume 
• one product change at a time 
• no relapse, except former 
smokers via e-cigs 
x 
“gateway 
to smoking” 
x 
x x 
x 
relapse 
by former 
smoker 
via e-cigs 
x x
© 
Data sources include: 
For cigarette smoking initiation, prevalence, use levels, and cessation 
rates: US national surveys, with age and gender breakdown 
• National Survey on Drug Use and Health (NSDUH) 
• National Health Interview Survey (NHIS) 
• Tobacco Use Supplement to the Current Population Survey (TUS-CPS) 
• A decade or more of annual data allows model calibration 
For smoking-related mortality: large survey-based relative risk studies 
• By age, gender, use levels, time since quitting 
For e-cig use patterns: 
• Randomized controlled studies of smokers offered e-cigs 
• Surveys of e-cig use (problematic due to biases) 
• Studies of Swedish snus as a possible e-cigarette analog 
• In the 1970s snus started displacing cigarettes in Sweden, resulting 
in the lowest smoking rate in Europe for the past 15+ years. 
• BUT e-cig technology and use patterns are evolving quickly! 
13
Assuming a linear system with constant coefficients results in a weighted 
sum of matrix exponentials describing the states over time, e.g., smoker, 
e-cig user, dual user, former user, and never-user categories. 
Most population models are discrete, but continuous and discrete linear models are equivalent: 
© 
14 
Proportional transition rates “Survival” proportion Constant growth rate 
Continuous Discrete 
Equation 
(x is a vector, A & 
P are matrices) 
dx/dt = A x + b, 
x(0) = x0 
x(t+1) = P x(t) + B (t=0, 1, ...), 
x(0) = x0 
Units A: units of x/t (≥0) 
b: units of x 
P: no units (range 0-1) 
B: units of x 
xEquilibrium: x(∞) 
(dx/dt = 0, 
x(t+1) = x(t)) 
-A-1 b (I–P)-1 B 
Exponential aapppprrooaacchh ttoo eeqquuiilliibbrriiuumm 
Solution x(t) eAt x0 + (I-eAt) xEq Pt x0 + (I-Pt) xEq 
Equivalent if: P = eA, 
B = -(I-P) A-1 b
One insight from such linear models is that even if parameters are 
fixed, equilibrium (-A-1 b) may take centuries to reach. 
© 
15 
Former Smokers 
Current Smokers 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
90% 
80% 
70% 
60% 
50% 
40% 
30% 
20% 
10% 
0% 100% 
2000 2050 2100 2150 2200 
Never-Smoker Proportion 
Smoker Proportion 
Year 
Note Former Smoker prevalence increases, then decreases.
For flexibility, we use quasi Monte Carlo simulation of individual 
tobacco use histories across a large population. 
Most population health effect models define Markov states and 
calculate annual proportions of users in each state (deterministically). 
Advantage of individual simulation: the number of states considered is 
no longer a limitation. 
• E.g., mortality can be made a function of year of age, gender, 
smoking intensity, e-cig use status, former status history, etc 
Disadvantage: tens of thousands of individuals need to be simulated for 
stable results in each sub-category. 
Use of quasi Monte Carlo numbers (selected to cover the space rather 
than fully random) reduce this disadvantage, by reducing the number of 
simulated individuals needed by several-fold. 
© 
16
Probabilistic analysis translates input uncertainty into 
output uncertainty. 
Wide input distributions result in wide distributions on possible net 
health impacts of e-cigs, from negative to positive. 
• Wide distributions are more “honest” than point estimates 
-200,000 0 200,000 400,000 600,000 
© 
Deterministic and probabilistic sensitivity analysis 
show which variables are most important for 
reducing uncertainty on health impacts. 
• Tornado charts sweep one variable at a time 
through a range, sorting by bar length to form 
a tornado shape. 
Breakeven analysis shows how much beneficial effect (like switches 
from smoking to e-cigs) is needed to offset a harmful effect (like 
switches the other way). 
• Called “tipping point analysis” in Swedish Match’s 2014 snus 
application to the FDA’s Center for Tobacco Products. 
17 
0.80 
1.00 
0.38 
0.92 
0.9% 
0.4% 
0.35 
1.20 
1.85 
0.60 
1.10 
2.7% 
1.2% 
0.45 
Base
Key tasks in evaluating net health effects of e-cigs include: 
© 
Improve estimates and ranges of e-cig transition rates 
• Initiation, full and partial switching from cigarettes, relapse back to 
cigarettes, “gateway” from e-cigs to cigarettes, quit rates 
• Snus analogy is useful as a scenario 
• Elicit subjective ranges from an expert panel? 
• As a function of time (e.g., 2020 and 2050) 
• Conditioned on various e-cig market growth scenarios 
Adjust mortality rates to account for history of cigarette use levels 
• Critical because smokers trying e-cigs reduce, but are slow to 
eliminate, smoking. 
Predict impact of e-cigs on morbidity as well as mortality 
• Morbidity effects show up sooner than mortality effects. 
18
Abrams 2014. e-Cigarettes: Can we use them to make combusting of tobacco obsolete - end the “cigarette century” and its 
preventable deaths? Presentation to American Academy of Health Behavior 14th Annual Meeting. 
http://www.aahb.org/Resources/Pictures/Meetings/2014-Charleston/PPT%20Presentations/Sunday%20Welcome/Abrams.AAHB.3.13.v1.o.pdf 
© 
Thank you! Questions? 
19

More Related Content

What's hot

Bareham et al E-Cigarettes Controversies within the controversy
Bareham et al E-Cigarettes Controversies within the controversyBareham et al E-Cigarettes Controversies within the controversy
Bareham et al E-Cigarettes Controversies within the controversy
David Bareham
 
E-cigarettes: pros, cons and controversy
E-cigarettes: pros, cons and controversy E-cigarettes: pros, cons and controversy
E-cigarettes: pros, cons and controversy
Laura-Jane Smith
 
Michigan Vape Shops Near Me
Michigan Vape Shops Near MeMichigan Vape Shops Near Me
Michigan Vape Shops Near Me
DoieraSamuels
 
Vapes and E-Cigs: 101
Vapes and E-Cigs: 101Vapes and E-Cigs: 101
Vapes and E-Cigs: 101
Deborah Durkin Neyer
 
Electronic (e) cigarettes ntpc march 2014
Electronic (e) cigarettes ntpc march 2014Electronic (e) cigarettes ntpc march 2014
Electronic (e) cigarettes ntpc march 2014
dcuniversegirl
 
TABACCO AND NICOTINE PRODUCTS
TABACCO AND  NICOTINE PRODUCTSTABACCO AND  NICOTINE PRODUCTS
TABACCO AND NICOTINE PRODUCTS
Georgi Daskalov
 
Final Draft 8
Final Draft 8Final Draft 8
Final Draft 8
Rebecca Ngo
 
Vaping and tobacco: six things you need to know about harm reduction
Vaping and tobacco:  six things you need to know about harm reductionVaping and tobacco:  six things you need to know about harm reduction
Vaping and tobacco: six things you need to know about harm reduction
Clive Bates
 
The MRTP process - Seven provocations - FDLI webinar 30 July 2020
The MRTP process - Seven provocations - FDLI webinar 30 July 2020The MRTP process - Seven provocations - FDLI webinar 30 July 2020
The MRTP process - Seven provocations - FDLI webinar 30 July 2020
Clive Bates
 
NYU College of Global Health - E-cigarette seminar - New York
NYU College of Global Health - E-cigarette seminar - New YorkNYU College of Global Health - E-cigarette seminar - New York
NYU College of Global Health - E-cigarette seminar - New York
Clive Bates
 
Clive Bates presentation at TMA 2015
Clive Bates presentation at TMA 2015Clive Bates presentation at TMA 2015
Clive Bates presentation at TMA 2015
Clive Bates
 
The pros and cons of e- cigarettes
The pros and cons of e- cigarettesThe pros and cons of e- cigarettes
The pros and cons of e- cigarettes
marisimons86
 
12 weeks Switch to Vaping: Science of Vaping
12 weeks Switch to Vaping: Science of Vaping 12 weeks Switch to Vaping: Science of Vaping
12 weeks Switch to Vaping: Science of Vaping
Fontem Ventures
 
What should we be doing to prevent occupational diseases from hazardous subst...
What should we be doing to prevent occupational diseases from hazardous subst...What should we be doing to prevent occupational diseases from hazardous subst...
What should we be doing to prevent occupational diseases from hazardous subst...
Retired
 
Bad science - 10 insights for advocates
Bad science - 10 insights for advocatesBad science - 10 insights for advocates
Bad science - 10 insights for advocates
Clive Bates
 
Accelerating the National Progress to Reduce Tobacco Use
Accelerating the National Progress to Reduce Tobacco UseAccelerating the National Progress to Reduce Tobacco Use
Accelerating the National Progress to Reduce Tobacco Use
Georgia State School of Public Health
 

What's hot (16)

Bareham et al E-Cigarettes Controversies within the controversy
Bareham et al E-Cigarettes Controversies within the controversyBareham et al E-Cigarettes Controversies within the controversy
Bareham et al E-Cigarettes Controversies within the controversy
 
E-cigarettes: pros, cons and controversy
E-cigarettes: pros, cons and controversy E-cigarettes: pros, cons and controversy
E-cigarettes: pros, cons and controversy
 
Michigan Vape Shops Near Me
Michigan Vape Shops Near MeMichigan Vape Shops Near Me
Michigan Vape Shops Near Me
 
Vapes and E-Cigs: 101
Vapes and E-Cigs: 101Vapes and E-Cigs: 101
Vapes and E-Cigs: 101
 
Electronic (e) cigarettes ntpc march 2014
Electronic (e) cigarettes ntpc march 2014Electronic (e) cigarettes ntpc march 2014
Electronic (e) cigarettes ntpc march 2014
 
TABACCO AND NICOTINE PRODUCTS
TABACCO AND  NICOTINE PRODUCTSTABACCO AND  NICOTINE PRODUCTS
TABACCO AND NICOTINE PRODUCTS
 
Final Draft 8
Final Draft 8Final Draft 8
Final Draft 8
 
Vaping and tobacco: six things you need to know about harm reduction
Vaping and tobacco:  six things you need to know about harm reductionVaping and tobacco:  six things you need to know about harm reduction
Vaping and tobacco: six things you need to know about harm reduction
 
The MRTP process - Seven provocations - FDLI webinar 30 July 2020
The MRTP process - Seven provocations - FDLI webinar 30 July 2020The MRTP process - Seven provocations - FDLI webinar 30 July 2020
The MRTP process - Seven provocations - FDLI webinar 30 July 2020
 
NYU College of Global Health - E-cigarette seminar - New York
NYU College of Global Health - E-cigarette seminar - New YorkNYU College of Global Health - E-cigarette seminar - New York
NYU College of Global Health - E-cigarette seminar - New York
 
Clive Bates presentation at TMA 2015
Clive Bates presentation at TMA 2015Clive Bates presentation at TMA 2015
Clive Bates presentation at TMA 2015
 
The pros and cons of e- cigarettes
The pros and cons of e- cigarettesThe pros and cons of e- cigarettes
The pros and cons of e- cigarettes
 
12 weeks Switch to Vaping: Science of Vaping
12 weeks Switch to Vaping: Science of Vaping 12 weeks Switch to Vaping: Science of Vaping
12 weeks Switch to Vaping: Science of Vaping
 
What should we be doing to prevent occupational diseases from hazardous subst...
What should we be doing to prevent occupational diseases from hazardous subst...What should we be doing to prevent occupational diseases from hazardous subst...
What should we be doing to prevent occupational diseases from hazardous subst...
 
Bad science - 10 insights for advocates
Bad science - 10 insights for advocatesBad science - 10 insights for advocates
Bad science - 10 insights for advocates
 
Accelerating the National Progress to Reduce Tobacco Use
Accelerating the National Progress to Reduce Tobacco UseAccelerating the National Progress to Reduce Tobacco Use
Accelerating the National Progress to Reduce Tobacco Use
 

Viewers also liked

iCloud
iCloudiCloud
iCloud
karissa1900
 
FACTS EVERY INBOUND MARKETER SHOULD KNOW
FACTS EVERY INBOUND MARKETER SHOULD KNOWFACTS EVERY INBOUND MARKETER SHOULD KNOW
FACTS EVERY INBOUND MARKETER SHOULD KNOW
Hillary Cox
 
What is netiquette
What is netiquetteWhat is netiquette
What is netiquette
Saket Srivastav
 
Slides intervento dott. Gasparin al convegno "La Provincia che verrà..." - Ho...
Slides intervento dott. Gasparin al convegno "La Provincia che verrà..." - Ho...Slides intervento dott. Gasparin al convegno "La Provincia che verrà..." - Ho...
Slides intervento dott. Gasparin al convegno "La Provincia che verrà..." - Ho...
clodovaldoruffato
 
Trabajo practico
Trabajo practicoTrabajo practico
Trabajo practico
karenMagali_
 
Manual de establecimiento de pasturas
Manual de establecimiento de pasturasManual de establecimiento de pasturas
Manual de establecimiento de pasturas
razasbovinasdecolombia
 
Rate Cards and Commentary
Rate Cards and CommentaryRate Cards and Commentary
Rate Cards and Commentary
_hayley_
 
Meritorious Selection and Service - NIT Tiruchirappalli
Meritorious Selection and Service - NIT TiruchirappalliMeritorious Selection and Service - NIT Tiruchirappalli
Meritorious Selection and Service - NIT Tiruchirappalli
Samuel Ernest
 
Whte Paper: Using aws for disaster recovery
Whte Paper:  Using aws for disaster recoveryWhte Paper:  Using aws for disaster recovery
Whte Paper: Using aws for disaster recovery
PBTAdvantage
 
Film Referencing
Film ReferencingFilm Referencing
Film Referencing
Syed Shan Tariq
 
Situación de aprendizaje
Situación de aprendizajeSituación de aprendizaje
Situación de aprendizaje
Servando Chavez
 
Bi kip tan gai (quarker)
Bi kip tan gai (quarker)Bi kip tan gai (quarker)
Bi kip tan gai (quarker)
Alex Tí
 
Web quest
Web questWeb quest
Web quest
dingess60
 
Tugas 1 wireless
Tugas 1 wirelessTugas 1 wireless
Tugas 1 wireless
Bayu Januar
 
La porta de l'aire
La porta de l'aireLa porta de l'aire
La porta de l'aire
siseA
 
Shot list
Shot listShot list
Shot list
Syed Shan Tariq
 
Director research
Director researchDirector research
Director research
Syed Shan Tariq
 
IT Case Competition Case 2015
IT Case Competition Case 2015IT Case Competition Case 2015
IT Case Competition Case 2015
Stefan K. Johansen
 

Viewers also liked (19)

iCloud
iCloudiCloud
iCloud
 
FACTS EVERY INBOUND MARKETER SHOULD KNOW
FACTS EVERY INBOUND MARKETER SHOULD KNOWFACTS EVERY INBOUND MARKETER SHOULD KNOW
FACTS EVERY INBOUND MARKETER SHOULD KNOW
 
What is netiquette
What is netiquetteWhat is netiquette
What is netiquette
 
Slides intervento dott. Gasparin al convegno "La Provincia che verrà..." - Ho...
Slides intervento dott. Gasparin al convegno "La Provincia che verrà..." - Ho...Slides intervento dott. Gasparin al convegno "La Provincia che verrà..." - Ho...
Slides intervento dott. Gasparin al convegno "La Provincia che verrà..." - Ho...
 
Trabajo practico
Trabajo practicoTrabajo practico
Trabajo practico
 
Manual de establecimiento de pasturas
Manual de establecimiento de pasturasManual de establecimiento de pasturas
Manual de establecimiento de pasturas
 
Rate Cards and Commentary
Rate Cards and CommentaryRate Cards and Commentary
Rate Cards and Commentary
 
Meritorious Selection and Service - NIT Tiruchirappalli
Meritorious Selection and Service - NIT TiruchirappalliMeritorious Selection and Service - NIT Tiruchirappalli
Meritorious Selection and Service - NIT Tiruchirappalli
 
Whte Paper: Using aws for disaster recovery
Whte Paper:  Using aws for disaster recoveryWhte Paper:  Using aws for disaster recovery
Whte Paper: Using aws for disaster recovery
 
Film Referencing
Film ReferencingFilm Referencing
Film Referencing
 
Situación de aprendizaje
Situación de aprendizajeSituación de aprendizaje
Situación de aprendizaje
 
Bi kip tan gai (quarker)
Bi kip tan gai (quarker)Bi kip tan gai (quarker)
Bi kip tan gai (quarker)
 
Web quest
Web questWeb quest
Web quest
 
Tugas 1 wireless
Tugas 1 wirelessTugas 1 wireless
Tugas 1 wireless
 
La porta de l'aire
La porta de l'aireLa porta de l'aire
La porta de l'aire
 
Shot list
Shot listShot list
Shot list
 
HaTrongDuong
HaTrongDuongHaTrongDuong
HaTrongDuong
 
Director research
Director researchDirector research
Director research
 
IT Case Competition Case 2015
IT Case Competition Case 2015IT Case Competition Case 2015
IT Case Competition Case 2015
 

Similar to E-Cigarettes: Promise, Peril, and Probabilistic Population Prediction

Lisbon Addictions 2019 Safer Nicotine Products
Lisbon Addictions 2019 Safer Nicotine ProductsLisbon Addictions 2019 Safer Nicotine Products
Lisbon Addictions 2019 Safer Nicotine Products
LynneDawkins
 
Tobacco Harm Reduction - an introduction
Tobacco Harm Reduction - an introductionTobacco Harm Reduction - an introduction
Tobacco Harm Reduction - an introduction
Clive Bates
 
Cigarettes on the cardiovascular system
Cigarettes on the cardiovascular systemCigarettes on the cardiovascular system
Cigarettes on the cardiovascular system
Ramachandra Barik
 
Visualising possible scenarios with ENDS (Electronic Nicotine Delivery Systems)
Visualising possible scenarios with ENDS (Electronic Nicotine Delivery Systems)Visualising possible scenarios with ENDS (Electronic Nicotine Delivery Systems)
Visualising possible scenarios with ENDS (Electronic Nicotine Delivery Systems)
UCT ICO
 
Vapours vs cigarettes research
Vapours vs cigarettes researchVapours vs cigarettes research
Vapours vs cigarettes research
wolllfie
 
Wells Fargo 2013
Wells Fargo 2013 Wells Fargo 2013
Wells Fargo 2013
Clive Bates
 
Innovation for Consumers: E-cigarettes and novel tobacco products - Part of t...
Innovation for Consumers: E-cigarettes and novel tobacco products - Part of t...Innovation for Consumers: E-cigarettes and novel tobacco products - Part of t...
Innovation for Consumers: E-cigarettes and novel tobacco products - Part of t...
Clive Bates
 
bardellini2017 (1).pdf
bardellini2017 (1).pdfbardellini2017 (1).pdf
bardellini2017 (1).pdf
EstefanaPuello
 
Tobacco Harm Reduction_Crimson Publishers
Tobacco Harm Reduction_Crimson PublishersTobacco Harm Reduction_Crimson Publishers
Tobacco Harm Reduction_Crimson Publishers
CrimsonpublishersTTEH
 
Tobacco harm reduction - meetings with Hill staff
Tobacco harm reduction - meetings with Hill staff Tobacco harm reduction - meetings with Hill staff
Tobacco harm reduction - meetings with Hill staff
Clive Bates
 
Benefits of Electronic Cigarettes
Benefits of Electronic CigarettesBenefits of Electronic Cigarettes
Benefits of Electronic Cigarettes
Inlyte eCigs
 
In the current write up, Supervisor Support has been used as one o.docx
In the current write up, Supervisor Support has been used as one o.docxIn the current write up, Supervisor Support has been used as one o.docx
In the current write up, Supervisor Support has been used as one o.docx
bradburgess22840
 
MPs Advocate For More Relaxed E-cigarette Rules | Jenn Galandy
MPs Advocate For More Relaxed E-cigarette Rules | Jenn Galandy MPs Advocate For More Relaxed E-cigarette Rules | Jenn Galandy
MPs Advocate For More Relaxed E-cigarette Rules | Jenn Galandy
Jenn Galandy, MA
 
e cig
e cige cig
Effects of substituting cigarettes with e-cigarettes in adult smokers
Effects of substituting cigarettes with e-cigarettes in adult smokers Effects of substituting cigarettes with e-cigarettes in adult smokers
Effects of substituting cigarettes with e-cigarettes in adult smokers
Fontem Ventures
 
Respect Vapers Ireland - webinar on tobacco harm reduction
Respect Vapers Ireland - webinar on tobacco harm reductionRespect Vapers Ireland - webinar on tobacco harm reduction
Respect Vapers Ireland - webinar on tobacco harm reduction
Clive Bates
 
EAI - Special Report - Ecigs
EAI  - Special Report - EcigsEAI  - Special Report - Ecigs
EAI - Special Report - Ecigs
adel mhiri
 
Vaping and Tobacco Harm Reduction
Vaping and Tobacco Harm ReductionVaping and Tobacco Harm Reduction
Vaping and Tobacco Harm Reduction
Clive Bates
 
Nicotine Rapid Test Kit Presentation
Nicotine Rapid Test Kit PresentationNicotine Rapid Test Kit Presentation
Nicotine Rapid Test Kit Presentation
Pammvi Group of Companies
 
Article Review Grading Rubric Grade Calculation (Summary .docx
Article Review Grading Rubric Grade Calculation (Summary  .docxArticle Review Grading Rubric Grade Calculation (Summary  .docx
Article Review Grading Rubric Grade Calculation (Summary .docx
rossskuddershamus
 

Similar to E-Cigarettes: Promise, Peril, and Probabilistic Population Prediction (20)

Lisbon Addictions 2019 Safer Nicotine Products
Lisbon Addictions 2019 Safer Nicotine ProductsLisbon Addictions 2019 Safer Nicotine Products
Lisbon Addictions 2019 Safer Nicotine Products
 
Tobacco Harm Reduction - an introduction
Tobacco Harm Reduction - an introductionTobacco Harm Reduction - an introduction
Tobacco Harm Reduction - an introduction
 
Cigarettes on the cardiovascular system
Cigarettes on the cardiovascular systemCigarettes on the cardiovascular system
Cigarettes on the cardiovascular system
 
Visualising possible scenarios with ENDS (Electronic Nicotine Delivery Systems)
Visualising possible scenarios with ENDS (Electronic Nicotine Delivery Systems)Visualising possible scenarios with ENDS (Electronic Nicotine Delivery Systems)
Visualising possible scenarios with ENDS (Electronic Nicotine Delivery Systems)
 
Vapours vs cigarettes research
Vapours vs cigarettes researchVapours vs cigarettes research
Vapours vs cigarettes research
 
Wells Fargo 2013
Wells Fargo 2013 Wells Fargo 2013
Wells Fargo 2013
 
Innovation for Consumers: E-cigarettes and novel tobacco products - Part of t...
Innovation for Consumers: E-cigarettes and novel tobacco products - Part of t...Innovation for Consumers: E-cigarettes and novel tobacco products - Part of t...
Innovation for Consumers: E-cigarettes and novel tobacco products - Part of t...
 
bardellini2017 (1).pdf
bardellini2017 (1).pdfbardellini2017 (1).pdf
bardellini2017 (1).pdf
 
Tobacco Harm Reduction_Crimson Publishers
Tobacco Harm Reduction_Crimson PublishersTobacco Harm Reduction_Crimson Publishers
Tobacco Harm Reduction_Crimson Publishers
 
Tobacco harm reduction - meetings with Hill staff
Tobacco harm reduction - meetings with Hill staff Tobacco harm reduction - meetings with Hill staff
Tobacco harm reduction - meetings with Hill staff
 
Benefits of Electronic Cigarettes
Benefits of Electronic CigarettesBenefits of Electronic Cigarettes
Benefits of Electronic Cigarettes
 
In the current write up, Supervisor Support has been used as one o.docx
In the current write up, Supervisor Support has been used as one o.docxIn the current write up, Supervisor Support has been used as one o.docx
In the current write up, Supervisor Support has been used as one o.docx
 
MPs Advocate For More Relaxed E-cigarette Rules | Jenn Galandy
MPs Advocate For More Relaxed E-cigarette Rules | Jenn Galandy MPs Advocate For More Relaxed E-cigarette Rules | Jenn Galandy
MPs Advocate For More Relaxed E-cigarette Rules | Jenn Galandy
 
e cig
e cige cig
e cig
 
Effects of substituting cigarettes with e-cigarettes in adult smokers
Effects of substituting cigarettes with e-cigarettes in adult smokers Effects of substituting cigarettes with e-cigarettes in adult smokers
Effects of substituting cigarettes with e-cigarettes in adult smokers
 
Respect Vapers Ireland - webinar on tobacco harm reduction
Respect Vapers Ireland - webinar on tobacco harm reductionRespect Vapers Ireland - webinar on tobacco harm reduction
Respect Vapers Ireland - webinar on tobacco harm reduction
 
EAI - Special Report - Ecigs
EAI  - Special Report - EcigsEAI  - Special Report - Ecigs
EAI - Special Report - Ecigs
 
Vaping and Tobacco Harm Reduction
Vaping and Tobacco Harm ReductionVaping and Tobacco Harm Reduction
Vaping and Tobacco Harm Reduction
 
Nicotine Rapid Test Kit Presentation
Nicotine Rapid Test Kit PresentationNicotine Rapid Test Kit Presentation
Nicotine Rapid Test Kit Presentation
 
Article Review Grading Rubric Grade Calculation (Summary .docx
Article Review Grading Rubric Grade Calculation (Summary  .docxArticle Review Grading Rubric Grade Calculation (Summary  .docx
Article Review Grading Rubric Grade Calculation (Summary .docx
 

More from Certara

A milestone in_scientific_publishing_print_infographic(1)
A milestone in_scientific_publishing_print_infographic(1)A milestone in_scientific_publishing_print_infographic(1)
A milestone in_scientific_publishing_print_infographic(1)
Certara
 
IQ consortium survey pkpd modeling in pharma
IQ consortium survey   pkpd modeling in pharmaIQ consortium survey   pkpd modeling in pharma
IQ consortium survey pkpd modeling in pharma
Certara
 
Martinez use of in silico models to support canine drug development
Martinez use of in silico models to support canine drug developmentMartinez use of in silico models to support canine drug development
Martinez use of in silico models to support canine drug development
Certara
 
Use of modelling and simulation to assess and manage individualized risk of d...
Use of modelling and simulation to assess and manage individualized risk of d...Use of modelling and simulation to assess and manage individualized risk of d...
Use of modelling and simulation to assess and manage individualized risk of d...
Certara
 
Reference scaled average bioequivalence analysis
Reference scaled average bioequivalence analysisReference scaled average bioequivalence analysis
Reference scaled average bioequivalence analysis
Certara
 
Trevor johnson aaps 2014
Trevor johnson   aaps 2014Trevor johnson   aaps 2014
Trevor johnson aaps 2014
Certara
 
Richard Cramer 2014 euro QSAR presentation
Richard Cramer 2014 euro QSAR presentationRichard Cramer 2014 euro QSAR presentation
Richard Cramer 2014 euro QSAR presentation
Certara
 

More from Certara (7)

A milestone in_scientific_publishing_print_infographic(1)
A milestone in_scientific_publishing_print_infographic(1)A milestone in_scientific_publishing_print_infographic(1)
A milestone in_scientific_publishing_print_infographic(1)
 
IQ consortium survey pkpd modeling in pharma
IQ consortium survey   pkpd modeling in pharmaIQ consortium survey   pkpd modeling in pharma
IQ consortium survey pkpd modeling in pharma
 
Martinez use of in silico models to support canine drug development
Martinez use of in silico models to support canine drug developmentMartinez use of in silico models to support canine drug development
Martinez use of in silico models to support canine drug development
 
Use of modelling and simulation to assess and manage individualized risk of d...
Use of modelling and simulation to assess and manage individualized risk of d...Use of modelling and simulation to assess and manage individualized risk of d...
Use of modelling and simulation to assess and manage individualized risk of d...
 
Reference scaled average bioequivalence analysis
Reference scaled average bioequivalence analysisReference scaled average bioequivalence analysis
Reference scaled average bioequivalence analysis
 
Trevor johnson aaps 2014
Trevor johnson   aaps 2014Trevor johnson   aaps 2014
Trevor johnson aaps 2014
 
Richard Cramer 2014 euro QSAR presentation
Richard Cramer 2014 euro QSAR presentationRichard Cramer 2014 euro QSAR presentation
Richard Cramer 2014 euro QSAR presentation
 

Recently uploaded

Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
Jim Jacob Roy
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
NX Healthcare
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
Gokuldas Hospital
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
FFragrant
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Pratik328635
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
anaghabharat01
 

Recently uploaded (20)

Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
 

E-Cigarettes: Promise, Peril, and Probabilistic Population Prediction

  • 1. E-cigarettes, which deliver nicotine without carcinogenic tar, hold the promise to save the lives of many smokers who switch to them, but risks include failure to quit cigarettes (dual use), increased initiation to nicotine products among youth, relapse of former smokers to e-cigarettes, and e-cigarettes becoming a “gateway to smoking.” To capture these uncertainties and weigh benefits vs. risks, prediction of e-cigarette health impacts must use a broad range of probability-weighted scenarios. © E-Cigarettes: Promise, Peril, and Probabilistic Population Prediction Bill Poland, PhD Bill.Poland@Certara.com INFORMS Annual Meeting, 10 November 2014
  • 2. After the “cigarette century”: what’s the end game? © 2 http://www.surgeongeneral.gov/library/reports/50-years-of-progress/index.html#fullreport 2014
  • 3. Smoking still kills about 480,000 Americans per year, reducing life spans 11-12 years. © 3 http://www.surgeongeneral.gov/library/reports/50-years-of-progress/index.html#fullreport
  • 4. Sales of e-cigarettes have been roughly doubling annually since US introduction in 2007 and could overtake cigarettes by 2023*, raising hopes and fears. © Sugerman DT. e-Cigarettes. JAMA 2014;311(2):212. http://jama.jamanetwork.com/article.aspx?articleid=1812964 * Herzog B, Wells Fargo Securities presentation, 2014. http://www.ecigarette-politics.com/files/WF-DallasMarch2014.ppt 4
  • 5. Cigarettes deliver nicotine (addictive but relatively safe) and tar (toxic partially combusted tobacco); e-cigs avoid the tar. © Nicotine Produced by the tobacco plant as a natural pesticide • Used as a pesticide in early 1900s Highly addictive for many, mildly addictive for others Suggestion but no solid evidence linking to cancer • Ames assay for genotoxicity negative • But promotes angiogenesis and tumors in some experimental models Exposure during adolescence and in utero appears to cause long-term brain changes Nicotine Replacement Therapy (NRT) such as patches and gum, and drugs like Chantix, minimize addiction risk but have a low success rate Tar Contains hundreds of mutagens, carcinogens, and other toxins • “Cigarette smoking has been causally linked to diseases of nearly all organs of the body” • Surgeon General’s Report, 2014 • Top diseases: lung cancer, COPD, CHD • Also diabetes, rheumatoid arthritis, and colorectal cancer, as well as inflammation and impaired immune function. Damages lungs (coats the cilia causing them to stop working and eventually die) and mouth. 5
  • 6. One eminent researcher concluded “e-cigarettes, with prudent ... regulations, do have the potential to make the combusting of tobacco obsolete ... just as digital cameras made film obsolete.” © 6 Abrams DB. JAMA 2014;311(2): 135-136. http://jama.jamanetwork.com/article.aspx?articleid=1812971
  • 7. Another researcher emphasizes a worst-case scenario. Time for probabilistic modeling! © Best Case Massive migration of smokers into e-cig vaping • Like digital cameras replacing film • CV and respiratory disease decline, followed by cancers Dual use is temporary Many e-cig users then quit nicotine entirely • Users work their way down to low and no-nicotine e-cigs • Total nicotine use drops Youths who would have smoked take up e-cigs instead Long-term vapor inhalation is found safe. Worst Case Massive migration of smokers and non-smokers into e-cig vaping • Like cell phone adoption • Non-users drawn in by purported safety Dual use persists • Mortality benefit of fewer cigarettes smoked/day is less than hoped E-cigs attract youth and experimenters, addict them to nicotine, and become a “gateway to smoking” E-cigarette advertising renormalizes tobacco product use so that smoking prevalence increases. Long-term exposure to fine particles in vapor turns out to be harmful. 7
  • 8. Mendez D 2011. Modeling the Population Dynamics of Smoking Prevalence and Health Effects, Washington DC, 9 May2011. © Population models predict smoking prevalence and mortality under various scenarios. 8 http://www.iom.edu/~/media/Files/Activity%20Files/PublicHealth/ReducedRiskTobacco/MendezPresentation.pdf
  • 9. Mortality risk relative to nonsmokers has been modeled vs. years since quitting. Quitting by 40 may return risk to non-smoker levels. Mendez D, Warner KE 2001. “The relative risk of death for former smokers: the influence of age and years-quit.” Unpublished © 9 research monograph. www.umich.edu/~dmendez/tobacco/RRiskmonograph.doc
  • 10. Few attempts have been made to relate mortality to use levels (intensity)—important with e-cigs. Here a Tobacco Exposure Index balances lifetime smoke toxin accumulation with natural purging. Miller LS et al. 2010. Evaluation of the economic impact of California’s Tobacco Control Program: a dynamic model approach. Tobacco Control 19(Suppl 1):i68-i76. http://tobaccocontrol.bmj.com/content/19/Suppl_1/i68.full.pdf © 10 2 packs/day never-smoker
  • 11. A new generation of population models tries to predict effects of two tobacco products and dual use. Verzi S 2014. http://www.fda.gov/downloads/Advis oryCommittees/CommitteesMeetingMa terials/TobaccoProductsScientificAdvis oryCommittee/UCM394231.pdf © 11 Cigarette/e-cig “gateway to smoking” relapse by former smoker via e-cigs
  • 12. © Even with simplifications, over a dozen highly uncertain transition rates remain. 12 Cigarette/e-cig x x x x x x Assume • one product change at a time • no relapse, except former smokers via e-cigs x “gateway to smoking” x x x x relapse by former smoker via e-cigs x x
  • 13. © Data sources include: For cigarette smoking initiation, prevalence, use levels, and cessation rates: US national surveys, with age and gender breakdown • National Survey on Drug Use and Health (NSDUH) • National Health Interview Survey (NHIS) • Tobacco Use Supplement to the Current Population Survey (TUS-CPS) • A decade or more of annual data allows model calibration For smoking-related mortality: large survey-based relative risk studies • By age, gender, use levels, time since quitting For e-cig use patterns: • Randomized controlled studies of smokers offered e-cigs • Surveys of e-cig use (problematic due to biases) • Studies of Swedish snus as a possible e-cigarette analog • In the 1970s snus started displacing cigarettes in Sweden, resulting in the lowest smoking rate in Europe for the past 15+ years. • BUT e-cig technology and use patterns are evolving quickly! 13
  • 14. Assuming a linear system with constant coefficients results in a weighted sum of matrix exponentials describing the states over time, e.g., smoker, e-cig user, dual user, former user, and never-user categories. Most population models are discrete, but continuous and discrete linear models are equivalent: © 14 Proportional transition rates “Survival” proportion Constant growth rate Continuous Discrete Equation (x is a vector, A & P are matrices) dx/dt = A x + b, x(0) = x0 x(t+1) = P x(t) + B (t=0, 1, ...), x(0) = x0 Units A: units of x/t (≥0) b: units of x P: no units (range 0-1) B: units of x xEquilibrium: x(∞) (dx/dt = 0, x(t+1) = x(t)) -A-1 b (I–P)-1 B Exponential aapppprrooaacchh ttoo eeqquuiilliibbrriiuumm Solution x(t) eAt x0 + (I-eAt) xEq Pt x0 + (I-Pt) xEq Equivalent if: P = eA, B = -(I-P) A-1 b
  • 15. One insight from such linear models is that even if parameters are fixed, equilibrium (-A-1 b) may take centuries to reach. © 15 Former Smokers Current Smokers 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 100% 2000 2050 2100 2150 2200 Never-Smoker Proportion Smoker Proportion Year Note Former Smoker prevalence increases, then decreases.
  • 16. For flexibility, we use quasi Monte Carlo simulation of individual tobacco use histories across a large population. Most population health effect models define Markov states and calculate annual proportions of users in each state (deterministically). Advantage of individual simulation: the number of states considered is no longer a limitation. • E.g., mortality can be made a function of year of age, gender, smoking intensity, e-cig use status, former status history, etc Disadvantage: tens of thousands of individuals need to be simulated for stable results in each sub-category. Use of quasi Monte Carlo numbers (selected to cover the space rather than fully random) reduce this disadvantage, by reducing the number of simulated individuals needed by several-fold. © 16
  • 17. Probabilistic analysis translates input uncertainty into output uncertainty. Wide input distributions result in wide distributions on possible net health impacts of e-cigs, from negative to positive. • Wide distributions are more “honest” than point estimates -200,000 0 200,000 400,000 600,000 © Deterministic and probabilistic sensitivity analysis show which variables are most important for reducing uncertainty on health impacts. • Tornado charts sweep one variable at a time through a range, sorting by bar length to form a tornado shape. Breakeven analysis shows how much beneficial effect (like switches from smoking to e-cigs) is needed to offset a harmful effect (like switches the other way). • Called “tipping point analysis” in Swedish Match’s 2014 snus application to the FDA’s Center for Tobacco Products. 17 0.80 1.00 0.38 0.92 0.9% 0.4% 0.35 1.20 1.85 0.60 1.10 2.7% 1.2% 0.45 Base
  • 18. Key tasks in evaluating net health effects of e-cigs include: © Improve estimates and ranges of e-cig transition rates • Initiation, full and partial switching from cigarettes, relapse back to cigarettes, “gateway” from e-cigs to cigarettes, quit rates • Snus analogy is useful as a scenario • Elicit subjective ranges from an expert panel? • As a function of time (e.g., 2020 and 2050) • Conditioned on various e-cig market growth scenarios Adjust mortality rates to account for history of cigarette use levels • Critical because smokers trying e-cigs reduce, but are slow to eliminate, smoking. Predict impact of e-cigs on morbidity as well as mortality • Morbidity effects show up sooner than mortality effects. 18
  • 19. Abrams 2014. e-Cigarettes: Can we use them to make combusting of tobacco obsolete - end the “cigarette century” and its preventable deaths? Presentation to American Academy of Health Behavior 14th Annual Meeting. http://www.aahb.org/Resources/Pictures/Meetings/2014-Charleston/PPT%20Presentations/Sunday%20Welcome/Abrams.AAHB.3.13.v1.o.pdf © Thank you! Questions? 19

Editor's Notes

  1. 1300/day
  2. The purge rate declines with age.